Proactive Investors - Run By Investors For Investors

Creso Pharma and Virbac launches hemp‐based animal feed product in Switzerland

Virbac is one of the top 10 veterinary pharmaceutical companies in the world.
a plant
Anibidiol is a natural complementary feed

Creso Pharma Ltd (ASX:CPH) and Virbac SA (EPA:VIRP) have launched Anibidiol®, a hemp‐based complementary animal feed product in Switzerland.

Anibidiol is a natural complementary feed for companion animals containing a standardised amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant.

Creso has developed and will manufacture the product and Virbac will launch, market and promote it to veterinarians and pet owners.

Virbac is headquartered in France and is one of the top 10 veterinary pharmaceutical companies in the world.

Creso and Virbac had signed an agreement in September 2017, which will remain in effect for at least 3 years, in Switzerland and Lichtenstein.

Creso’s anibidiol®1.25 and anibidiol® 2.5 are designed for companion animals such as dogs and cats and come in proprietary granule formulations.

Anibidiol promotes the well-being of the animal by supporting its immunity and natural defence system. The product also supports the pet’s balanced behaviour.

The recession-resistant worldwide animal health market is valued at circa US$30 billion.

It is worth noting that 41% of pet owners have considered or tried various alternative therapies including nutritional supplements (29%) and herbal remedies (7%).

Creso’s share price increased circa 45% during the past one month, last closing at $0.80.

View full CPH profile View Profile

Related Articles

porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use